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Expression of Murine 5-Aminolevulinate Synthase
Variants Causes Protoporphyrin IX Accumulation and
Light-Induced Mammalian Cell Death
Erica J. Fratz1, Gregory A. Hunter1, Gloria C. Ferreira1,2*
1 Department of Molecular Medicine, Morsani College of Medicine, Tampa, Florida, United States of America, 2 Department of Chemistry, University of South Florida,
Tampa, Florida, United States of America

Abstract
5-Aminolevulinate synthase (ALAS; EC 2.3.1.37) catalyzes the first committed step of heme biosynthesis in animals. The
erythroid-specific ALAS isozyme (ALAS2) is negatively regulated by heme at the level of mitochondrial import and, in its
mature form, certain mutations of the murine ALAS2 active site loop result in increased production of protoporphyrin IX
(PPIX), the precursor for heme. Importantly, generation of PPIX is a crucial component in the widely used photodynamic
therapies (PDT) of cancer and other dysplasias. ALAS2 variants that cause high levels of PPIX accumulation provide a new
means of targeted, and potentially enhanced, photosensitization. In order to assess the prospective utility of ALAS2 variants
in PPIX production for PDT, K562 human erythroleukemia cells and HeLa human cervical carcinoma cells were transfected
with expression plasmids for ALAS2 variants with greater enzymatic activity than the wild-type enzyme. The levels of
accumulated PPIX in ALAS2-expressing cells were analyzed using flow cytometry with fluorescence detection. Further, cells
expressing ALAS2 variants were subjected to white light treatments (21–22 kLux) for 10 minutes after which cell viability
was determined. Transfection of HeLa cells with expression plasmids for murine ALAS2 variants, specifically for those with
mutated mitochondrial presequences and a mutation in the active site loop, caused significant cellular accumulation of
PPIX, particularly in the membrane. Light treatments revealed that ALAS2 expression results in an increase in cell death in
comparison to aminolevulinic acid (ALA) treatment producing a similar amount of PPIX. The delivery of stable and highly
active ALAS2 variants has the potential to expand and improve upon current PDT regimes.
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important aspect of the import sequences in both ALAS1 [17]
and ALAS2 [18] are the presence of heme-regulatory motifs
(HRMs), which consist of short amino acid sequences characterized in part by adjacent cysteine-proline (CP) residues [19]. HRMs
confer heme-binding properties and have been shown to function
as heme-oxygen sensors in bacteria [20], yeast [21] and mammals
[18,22,23]. In in vitro translocation experiments with isolated
mitochondria and ALAS2 precursor protein, the two hemebinding motifs in the leader sequence, corresponding to C11 and
C38 in murine ALAS2 (mALAS2), were reported to bind heme
and prevent translocation of precursor ALAS2 into the mitochondrion [18]. Structural and biochemical data have also demonstrated that a heme-peptide interaction occurs between hemin and
the presequence of ALAS2 [24], further indicating the potential of
heme to act as a feedback inhibitor of the pathway by preventing
the mitochondrial import of precursor ALAS2 when heme levels
are sufficient for cellular requirements.
Much of what we know about the chemical and kinetic
mechanisms of ALAS2 comes from in vitro enzymatic assays that
have helped establish and define the microscopic steps of the
ALAS-catalyzed reaction, including the rates of glycine and
succinyl-CoA binding, formation of the quinonoid intermediates,

Introduction
The first committed step of heme biosynthesis in non-plant
eukaryotes and some prokaryotes, the pyridoxal 59-phosphate
(PLP)-dependent condensation of glycine and succinyl-coenzyme
A to generate 5-aminolevulinate (ALA), coenzyme A (CoA), and
CO2, is catalyzed by 5-aminolevulinate synthase (ALAS) [1,2].
This reaction is directly coupled to the citric acid cycle via the
substrate succinyl-CoA and is the key regulatory step of heme
biosynthesis [3]. In mammals, two chromosomally distinct genes
each encode an ALAS isoenzyme, and the two isoenzymes are
differentially expressed in a tissue specific manner [4]. The human
gene for the non-specific or housekeeping isoform, ALAS1, is
located on chromosome 3 [5,6], and is expressed ubiquitously in
all tissues [7]. The gene encoding the erythroid specific isoform,
ALAS2, is located on the x-chromosome [6,8] and is expressed
only in developing erythroblasts [7].
The two ALAS isoenzymes are translated as precursor proteins
with N-terminal mitochondrial matrix import signal sequences
that are proteolytically cleaved following importation to yield the
mature enzymes [9–12]. The activity of the enzyme is only
manifested upon localization to the mitochondrial matrix, as this is
where the substrate succinyl-CoA is produced [13–16]. An
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and product release [2,25–28]. These studies, performed using
mALAS2 purified from E. coli cells expressing the recombinant
mature enzyme, have led to an understanding of the importance of
specific regions and single amino acid residues in the intrinsic
activity of ALAS2 [29–35]. Generally, a mutation made to an
amino acid predicted to be of functional importance causes a
decrease in activity of the enzyme. For example, K313 of
mALAS2 was identified as the amino acid involved in the Schiff
base linkage with the PLP cofactor [36], and mutations in K313
completely abolish measurable activity of mALAS2 under
standard assay conditions [29,37]. However, some mutations in
mALAS2 cause significantly increased activity of the enzyme, as
demonstrated both using purified enzyme [31,35], and in bacteria
when expressing plasmids encoding the variant enzymes [35].
These mutations are all located in an extended conformation
region termed the active site loop (Y422-R439), which is predicted
to act as a ‘‘lid’’ over the active site following substrate binding
[35]. Thus, ALAS is thought to undergo a conformational change
from an open conformation, in which the substrates glycine and
succinyl-CoA can bind in the active site, to a closed conformation,
during which the products ALA, CoA, and CO2 are formed
[25,28]. When the reaction is complete, the active site loop
reopens, and the products are released. It is the opening of the
active site loop to allow product release that limits the overall rate
of the enzymatic reaction [2,25,27]. Based on a combination of
kinetic [25,28] and structural modeling studies [38], it was
proposed that mutations in the active site loop can lead to
hyperactive forms of ALAS, defined as those with at least a 10-fold
increase in catalytic efficiency toward one or both substrates, by
accelerating reversion to the open loop conformation upon
product formation [35].
Since ALAS catalyzes the rate-determining step of tetrapyrrole
biosynthesis in mammals [2,25], overexpression of ALAS in
prokaryotic [35] and eukaryotic cells [39] results in accumulation
of the photosensitizing heme precursor, protoporphyrin IX
(PPIX). This property has potential for applications of ALAS or
ALAS variants in photodynamic therapy of tumors and other nonmalignant dermatological indications, such as acne vulgaris,
psoriasis, and scleroderma [40,41]. In this study, we transfected
mammalian cells with mALAS2 variants and measured PPIX
accumulation using fluorescence activated cell sorting (FACS). We
identified the R433K variant with additional mutations of the
HRMs in the presequence as the variant causing the most cellular
PPIX accumulation. Subsequently, we used the variants causing
the most PPIX accumulation to study the cell death caused by the
PPIX toxicity and photosensitization.

lium bromide (MTT) was purchased from Sigma-Aldrich (St.
Louis, MO). BmtI and BamHI restriction enzymes were obtained
from New England BioLabs, Inc. G418 sulfate was procured from
Mediatech, Inc. (Manassas, VA).

Plasmids
The precursor ALAS2 cDNAs were individually subcloned into
the multiple cloning site of the pIRES2-ZsGreen1 vector
(purchased from Clontech Laboratories, Inc. Mountain View,
CA) using the BmtI and BamHI restriction sites. Digested ALAS2encoding fragments were ligated into the digested pIRES2ZsGreen1 vector using T4 DNA ligase and ligase buffer (Thermo
Scientific Fermentas (Waltham, MA)). Electrocompetent
BL21(DE3) cells were transformed by electroporation with the
ligated plasmid DNA and selected by spreading them on LB agar
medium containing 10 mg/mL kanamycin sulfate. Plasmid DNA
was purified from a single colony using a QiaPrep Spin Miniprep
kit (Qiagen Inc.; Germantown, MD), and the sequence of the
cloned DNA was verified by Genewiz, Inc. (New Brunswick, NJ).

Cell Culture
K562 human immortalized myelogenous leukemia cells
(ATCC) were maintained in RPMI-1640 culture medium,
purchased from Mediatech, Inc. (Manassas, VA), with 10% fetal
bovine serum (FBS; purchased from Thermo Scientific Waltham,
MA), gentamicin (50 mg/mL), penicillin (60 mg/mL) and streptomycin (100 mg/mL) at 37uC in a humidified incubator with 5%
CO2. HeLa human cervical carcinoma cells (ATCC) were
maintained in DMEM culture medium with 4.5 g/L glucose, Lglutamine, and sodium pyruvate (Mediatech, Inc.; Manassas, VA),
with 10% fetal bovine serum (FBS), gentamicin (50 mg/mL),
penicillin (60 mg/mL) and streptomycin (100 mg/mL) at 37uC in a
humidified incubator with 5% CO2.

Stable Transfection of K562 Human Erythroleukemia Cells
K562 cells were transfected with Lipofectamine LTX and
PLUS Reagent, purchased from Invitrogen (San Jose, CA),
according to the supplier’s optimized protocol for K562 cells.
On the day of transfection, a hemocytometer and trypan blue
staining were used to count the cells and determine culture density
and viability. In a 6-well plate, K562 cells (56105 cells per well)
were seeded in a 6-well plate at a volume of 2 mL of RPMI-1640
growth medium with 10% FBS 30 minutes prior to transfection.
For each transfection, 2.5 mg of DNA was added into 500 mL of
RPMI medium without serum. 2.5 mL of PLUS reagent (at a 1:1
ratio to DNA) was then added directly to the diluted DNA. After
gentle mixing and a 10 minute incubation at room temperature,
10 mL of Lipofectamine LTX was added into the diluted DNA
solution, mixed gently and incubated for 35 minutes at room
temperature to form DNA-Lipofectamine LTX complexes. The
DNA-Lipofectamine LTX complexes were added dropwise to
each well containing cells and mixed gently by manually rocking
the plate back and forth. 24 hours after transfection, the cells were
pelleted by centrifugation at 4006g and resuspended in RPMI1640 culture medium with 10% FBS, gentamicin (50 mg/mL) and
the selection antibiotic, G418 sulfate (500 mg/mL). Every 2–3
days, the cells were pelleted and resuspended in fresh medium with
10% FBS, gentamicin (50 mg/mL), and G418 sulfate (500 mg/
mL). Assays were performed 2–6 weeks after the start of selection.

Materials and Methods
Materials
5-Aminolevulinic acid hydrochloride (ALA) was purchased from
Acros Organics (Morris Plains, NJ), and dissolved in distilled water
at a concentration of 10 mg/mL. Glycine, purchased from Fisher
Chemical (Fairlawn, NJ), was dissolved in phenol red-free culture
medium purchased from Mediatech, Inc. (Manassas, VA) to give a
stock concentration of 1 M. Paclitaxel (6 mg/mL stock in DMSO)
was graciously provided by the laboratory of Dr. Scott Antonia (H.
Lee Moffitt Cancer Center and Research Institute, Tampa, FL),
and was diluted in culture medium directly before use. Deferoxamine mesylate, purchased from Sigma (St. Louis, MO), was
dissolved in distilled water to create a 10 mM stock solution.
Propidium iodide, 49,6-diamidino-2-phenylindole (DAPI) and
kanamycin sulfate were purchased from Acros Organics (Morris
Plains, NJ), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoPLOS ONE | www.plosone.org

Transient Transfection of Hela Cells
On the day prior to transfection, HeLa cells were trypsinized
and counted. Approximately 26104 cells were seeded into each
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well of a 24-well plate in 0.5 mL of DMEM. Cell density was
,30–50% confluent on the day of transfection. For each
transfection, 250 ng of DNA was diluted into 100 ml of DMEM
without serum. 1 ml of Lipofectamine LTX was added into the
diluted DNA solution, mixed gently and incubated for 30–
45 minutes at room temperature to form DNA-Lipofectamine
LTX complexes. The DNA-Lipofectamine LTX complexes were
added dropwise to each well containing cells and mixed gently by
manually rocking the plate back and forth for a few seconds. After
4 hours of incubation with the DNA-Lipofectamine LTX
complexes, the medium was aspirated out of each well and fresh
DMEM with 10% FBS, gentamicin (50 mg/mL), penicillin
(60 mg/mL) and streptomycin (100 mg/mL) was added to each
well of cells. Cells were incubated at 37uC in a CO2 incubator for
24 or 48 hours post-transfection before assaying.

Cell Viability Assays
Cell death was assessed by measuring incorporation of either
propidium iodide or DAPI into nuclear DNA, as these fluorescent
dyes cross the plasma membrane in dying cells much more
efficiently than in live cells. HeLa cell cultures were independently
incubated with the fluorescent DNA-binding dyes propidium
iodide (10 mg/mL) and DAPI (10 mg/mL) for 5 min at 22uC. The
cells were then analyzed by determining the fluorescence
intensities using FACS. Fluorescence emission of nucleic acidbound propidium iodide was measured between 585 nm and
625 nm (605/40BP filter) upon excitation of the cells using the
488 nm laser, while DNA-bound DAPI emission was measured
between 440 nm and 460 nm (450/20BP filter) following excitation of the cells at 375 nm. Dot plots of SSC versus propidium
iodide or DAPI fluorescence were used to define the respective
gates, which were based on the control samples in which no
propidium iodide or DAPI were added. Cell viability was
independently determined using the MTT dye reduction assay
as described elsewhere [42,43]. HeLa cells (56103 cells per well)
were seeded in 96-well plates, and on the following day were
transfected with expression plasmids for mALAS2 variants as
described above. Twenty-four hours after plasmid transfection, or
4 hours after addition of 100 mM ALA, cells were exposed to light
for 10 minutes. The culture medium was pipetted out, 50 mL of
2 mg/mL MTT was added to each well, and cells were incubated
for an additional 4 hours at 37uC. Upon solubilization of the cells
with DMSO (100 mL/well) during a 10 minute incubation, the
solubilized, MTT-treated cells were thoroughly mixed by pipetting
several times, and absorbance was measured at 540 nm using a
mQuant plate reader (Bio-Tek Instruments, Inc.).

Preparation of Cells for FACS and Quantitation of PPIX
While K562 cells were suspended in phenol red-free medium,
HeLa cells were washed, scraped and resuspended in phosphatebuffered saline (PBS; 80 mM disodium hydrogen orthophosphate,
20 mM sodium dihydrogen orthophosphate, 100 mM sodium
chloride, pH 7.5) before pipetting into BD Falcon tubes with cell
strainer caps. Preparation of either K562 or HeLa cells for FACS
was done under very low light conditions (1–2 Lux as measured by
a Pyle PLMT68 light meter) in order to minimize phototoxicity
caused by PPIX accumulation. FACS analyses were performed
using a BD LSR II Analyzer (Becton, Dickinson, and Company)
and FACSDiva Version 6.1.3 software. ZsGreen1 emission was
measured between 515 nm and 545 nm (530/30BP filter) when
cells were excited using the 488 nm laser. In order to eliminate any
background red fluorescence, the 633 nm-red laser was blocked
during the collection of the PPIX emission data. PPIX emission
was determined in the 619 nm and 641 nm range (630/22BP
filter) when cells were excited with the 405 nm laser. Forwardscatter (FSC) versus side-scatter (SSC) dot plots were used to gate
the whole cells and thus remove the contribution of the cell debris
from the population being examined. A minimum of 10,000 of the
gated whole cells were then depicted in dot plots of SSC versus
ZsGreen1 fluorescence, and the ‘‘green-fluorescent population’’
gate was defined based on untransfected HeLa cells as negative
controls. Dot plots of SSC versus PPIX fluorescence were used to
define the PPIX-accumulating cells for both the ‘‘green-fluorescent’’ and the ‘‘non-green fluorescent’’ populations. The PPIX
gating was based on the negative control for PPIX, the pIRES2ZsGreen1 vector-expressing cells. PPIX fluorescence values were
normalized for transfection efficiency using the corresponding
ZsGreen1 fluorescence value.

Confocal Fluorescence Microscopy
HeLa cells were grown in Thermoscientific Nunc Labtek sterile
4-well chambered coverglass until 50% confluent, and then
transfected as described above. Six hours later, the culture
medium was supplemented with glycine to yield a final concentration of 100 mM, and immediately before obtaining confocal
fluorescence microscopy images of the cells, the medium was
removed from the wells and the cells were washed with PBS three
times. Live cell imaging was performed using a 3i-Olympus
spinning disk confocal microscope operated by Slidebook 5
software and equipped with a Photometrics Evolve EMCCD
camera. The filter block used consisted of a 350/50 nm excitation
filter, a BS400 beamsplitter, and a 630/75 nm emission filter.

Results
Transient Expression of Malas2 Variants Causes
Accumulation of PPIX in HeLa Cells

Light Exposure Assays

HeLa cells were transfected with mALAS2-encoding plasmids
with or without mutations in the mALAS2 presequence and/or
mature enzyme sequence (Table 1, Figure 1). Where indicated, the
mALAS2 presequence was mutated at three cysteine residues,
C11, C38, and C70, in order to yield nonfunctional HRMs and
thus eliminate heme feedback inhibition of mitochondrial import
[18,40]. The plasmids were designed such that a single bicistronic
mRNA, encoding both mALAS2 and the fluorescent protein
ZsGreen1, separated by an internal ribosomal entry site (IRES),
would be produced. Transcriptional expression of mALAS2 and
ZsGreen1 was under control of the constitutively active cytomegalovirus (CMV) promoter [44]. Twenty-four hours post-transfection, wild-type mALAS2 with a wild-type presequence (WTY)
expression caused a slight, but statistically significant as defined by
Student’s t-test (p,0.05), increase in PPIX accumulation

HeLa cells in 24-well plates were transfected 48 hours prior to
FACS analysis. Cells were washed twice with PBS and placed on
ice (to prevent overheating) underneath a Sylvania incandescent
flood lamp (150W, 120V) for 10 minutes. Light intensity at the
samples was measured before each light exposure experiment
using a Pyle PLMT68 light meter, and it was between 21–22 kLux
for all experiments. The samples were resuspended and pipetted
into tubes with cell strainer caps and analyzed first for ZsGreen1
and PPIX fluorescence (as described above), and then for cell
viability. In order to determine the statistical significance of cell
death directly attributable to mALAS2-induced PPIX accumulation and phototoxicity, samples were compared to the ZsGreen1
controls during t-test evaluations.

PLOS ONE | www.plosone.org
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(Figure 2A). The K313A mutation in ALAS2 leads to undetectable
enzymatic activity values in vitro [45], and under ex vivo conditions
this also appears to be the case, as no PPIX accumulated in
K313A-expressing cells (K313AY), a result similar to that of the
mammalian cells harboring the pIRES2-ZsGreen1 vector
(ZsGreen1) alone (Figure 2A). In comparison to WTY, the
heptavariant mutations in the active site loop alone (HPVTY)
and mutations in the presequence alone (WT) caused a statistically
significant (p,0.05) increase in PPIX production in expressing
cells (Figure 2A). The combination of the heptavariant mutations
in the active site loop and mutations in the presequence (HPVT)
resulted in variable PPIX production that was not statistically
significant. Somewhat unexpectedly, it was expression of the
mALAS2 variant with a mutated presequence containing the
R433K mutation (R433K) that caused the largest accumulation of
PPIX. Mutation of R433 residue to a lysine in the purified, mature
enzyme results in an increase in activity to twice that of the wildtype enzyme (i.e., a 2-fold increase in the kcat value and a 1.65 to
1.85-fold enhancement in the specificity constants for glycine and
succinyl-CoA over those of wild type, mature mALAS2) [31].
Similarly, the increase in PPIX accumulation in HeLa cells
expressing the R433K precursor with a mutated presequence was
approximately 2.5-fold compared to the cells expressing WTY and
2-fold in comparison to cells expressing WT (Figure 2A).
Because PPIX can be used as a photosensitizing agent for PDT
of cancers, we examined the effect of combining mALAS2induced PPIX accumulation with the chemotherapeutic drug
paclitaxel, a well-characterized inhibitor of mitosis [46–48]. Only
mALAS2 variants with mutated presequences were used in the
drug combination experiments, since those variants presented the
most potential for PPIX accumulation, and thus, subsequent cell
death resulting from light-induced phototoxicity. A dose response
curve revealed that the concentration of paclitaxel that killed 25%
of HeLa cells in 48 hours (IC25) was 10 nM (data not shown), and
this concentration was chosen as the desired concentration for the
PDT combination experiments. Paclitaxel had no statistically
significant effect, as defined by Student’s t-tests, on the amount of
accumulated PPIX in the mammalian cells transfected with any of
the ALAS2 variants after 48 hours (Figure 2B). The largest
increase in PPIX fluorescence was observed with the R433K
variant, regardless of whether or not paclitaxel was included in the
culture medium (Figure 2B).

Supplementation of Cell Culture Medium with Glycine
Leads to Increased PPIX Accumulation in Malas2expressing HeLa Cells
Given that PPIX is a photosensitizer [49] and the MichaelisMenten constant (Km) of mALAS2 for glycine, at 2564 mM
[3,25,34], is significantly higher than its intracellular concentration
of approximately 2.5 mM [50], it is plausible that supplementation
of the cell culture medium with glycine would lead to enhanced
synthesis of ALA, and consequently, PPIX, which in turn might
increase the efficacy of PPIX-induced phototoxicity. To examine
whether increased glycine concentration caused enhanced PPIX
accumulation, HeLa cells transfected with mALAS2 (wild type and
variants) were grown in medium with different glycine concentrations (Figure 3A). Samples with culture medium supplemented
with 100 mM ALA for 4 hours served as a control for PPIX
accumulation independent of glycine concentration (Figure 3B).
The concentration and treatment times for ALA were chosen
based on experiments indicating that the extent of PPIX
accumulated in HeLa cells supplemented with 100 mM ALA was
similar to that of HeLa cells expressing R433K, the mALAS2
variant that induces the highest levels of PPIX accumulation in
these cells (Figure S1). HeLa cells expressing WT, HPVT or
R433K in culture medium supplemented for 18 hours with
10 mM or 100 mM glycine exhibited significant increases in PPIX
in comparison to the ‘‘no glycine’’ controls, with R433K again
demonstrating the highest PPIX accumulation (p,0.01)
(Figure 4A). Supplementing the culture medium with either
10 mM or 100 mM glycine for cells expressing WT resulted in
approximately 4- and 6-fold increases in PPIX accumulation,
respectively, as compared to no glycine supplementation. For cells
expressing R433K, glycine supplementation more than tripled the
PPIX accumulation, representing a fourteen-fold increase over the
control HeLa cells supplemented with glycine. Cells expressing
HPVT were also affected by addition of either 10 mM or 100 mM
glycine, increasing the PPIX by 1.4-fold and 2.5-fold, respectively.
Glycine elicited no effect on PPIX production in HeLa cells alone,
those treated with 100 mM ALA, or HeLa cells expressing the
pIRES2-ZsGreen1 vector (Figure 3B).

Glycine and Deferoxamine Increase PPIX Accumulation in
Malas2-expressing K562 Cells
We generated stable K562 human myelogenous erythroleukemia cell lines expressing mALAS2, expecting that these cells might
accumulate high amounts of PPIX, due to their similarity to
undifferentiated erythrocytes [51]. We expressed only WT and
HPVT in order to test if HPVT could have higher activity in a cell
line in which ALAS2 in normally expressed. Initially, the stable
cell lines expressing WT did not show an increase in PPIX
fluorescence as compared to regular K562 cells (Figure 4A), and
we postulated that glycine availability was again a limiting factor,
as we had observed in HeLa cells (Figure 3). Another possible
limitation upon PPIX accumulation could be a more effective
conversion of PPIX into heme in K562 cells, in which case the
inclusion of an iron-specific chelator such as deferoxamine should
increase the PPIX fluorescence by reducing or even preventing
this conversion. To address why the expression of mALAS2 alone
did not cause a larger increase in PPIX and what could limit the
ALAS2-induced PPIX accumulation, the culture medium of K562
cells expressing (1) ZsGreen1 control, (2) WT, or (3) HPVT was
supplemented with glycine to yield final concentrations of 10 mM
or 100 mM glycine (Figure 4A and 4C) or deferoxamine mesylate
to yield a final concentration of 100 mM deferoxamine mesylate
(Figure 4B and 4D). Expression of WT in K562 cells did not

Figure 1. Murine ALAS2 protein schematic indicating mutated
amino acid residues. The green dotted lines represent the relative
locations of the three cysteines in the HRMs of ALAS2. C11 and C38 are
in the ALAS2 presequence. K313A, R433K, and the heptavariant
mutations and their respective positions are indicated according to
the amino acid numbering previously described for mature mALAS2
[31,35,36]. The amino acid positions according to the numbering for the
precursor enzyme are written above the diagram.
doi:10.1371/journal.pone.0093078.g001
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Figure 2. Porphyrin accumulation in transiently transfected HeLa cells with mALAS2 WT- and variant-expressing plasmids. (A) HeLa
cells transfected with mALAS2 variants with and without (Y) mutated presequences analyzed 24 hours after transfection. (B) HeLa cells transfected
with mALAS2 variants with mutated presequences, in cells cultured in the absence or presence of 10 nM paclitaxel (Pct), analyzed 48 hours after
transfection. Normalized PPIX fluorescence values were obtained by first dividing the mean PPIX fluorescence by the mean ZsGreen1 fluorescence for
each cell population and secondly dividing by the mean PPIX fluorescence/ZsGreen1 fluorescence ratio of the pIRES2-ZsGreen1-transfected cells.
Each data set represents three separate experiments 6 standard deviation (*p,0.05 and **p,0.01, Student’s t-test) [a.u., arbitrary units].
doi:10.1371/journal.pone.0093078.g002

Deferoxamine is a well-characterized iron-specific bacterial
siderophore with a long history of clinical use in iron chelation
therapy. Deferoxamine has the potential to increase PPIX by
decreasing the cellular iron concentration, thereby inhibiting the
conversion of PPIX to heme [52,53]. Treatment of K562 cells
with deferoxamine for 18 hours caused no change in PPIX
fluorescence in cells not expressing mALAS2 or cells expressing
HPVT. Deferoxamine did cause a significant increase in PPIX in
cells expressing WT, in which case the mean PPIX fluorescence

increase the cellular PPIX fluorescence, but PPIX fluorescence
increased by more than 5- and 10-fold when the culture medium
contained 10 mM glycine and 100 mM glycine, respectively
(Figure 4A). No significant differences were seen in cells not
expressing mALAS2 (Figure 4C) or in cells expressing HPVT
when treated with 10 mM glycine (Figure 4A). However, in
contrast to HeLa cells, when 100 mM glycine was used, cells
expressing HPVT did exhibit an increase in PPIX fluorescence by
approximately 3-fold (Figure 4A).

Table 1. Plasmid constructs used to express murine ALAS2 variants in mammalian cell lines.

Plasmid Name

Mutations in
mALAS2 Presequence

pIRES2-ZsGreen1
pEF21

N/A

1

Mature mALAS2 Sequence
N/A1

---

2

---2

2

V423L,Y428R,P432E, R433I, G434N, E435Q and L437K

pEF22

---

pEF23

---2

K313A

pEF24

C11S, C38S and C70S

---2

pEF25

C11S, C38S and C70S

V423L,Y428R,P432E, R433I, G434N, E435Q and L437K

pEF26

C11S, C38S and C70S

K313A

pEF31

C11S, C38S and C70S

R433K

1

N/A, non-applicable;
---, no mutations.
doi:10.1371/journal.pone.0093078.t001
2
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Figure 3. Glycine supplementation of culture medium increases PPIX accumulation in HeLa cells expressing murine wild-type,
HPVT, and R433K ALAS2. (A) PPIX fluorescence measured by flow cytometry 24 hours after transfection and 18 hours after supplementing culture
medium with 10 mM glycine or 100 mM glycine. The culture medium of the corresponding control cells and control transfected cells was not
supplemented with glycine. Normalized PPIX fluorescence values were obtained by dividing the mean PPIX fluorescence by the mean ZsGreen1
fluorescence for each cell population. Mean PPIX fluorescence values are representative of three separate experiments 6 standard deviation (*p,
0.05 and **p,0.01, Student’s t-test) [a.u., arbitrary units]. (B) ZsGreen1 fluorescence versus PPIX fluorescence in HeLa cell populations supplemented
with 100 mM glycine as measured by flow cytometry. In each dot plot, cells in the green-fluorescent range are represented in green and to the right
of the vertical black line, while cells that are not green-fluorescent are in blue. Cells that are red-fluorescent due to PPIX accumulation are above the
horizontal black line, while cells that are not red-fluorescent are below the horizontal black line. The percentage of cells in each quadrant is written in
the corners of each dot plot. ‘‘Control’’ refers to non-transfected HeLa cells.
doi:10.1371/journal.pone.0093078.g003

increased from 1.4-fold over cells expressing ZsGreen1, to 2.4-fold
with deferoxamine (Figure 4B and 4D).

ZsGreen1 (Figure 5B) or the R433K-expression plasmid
(Figures 5C and 5D). While the enzyme protoporphyrinogen
oxidase catalyzes PPIX production exclusively within the mitochondrion, PPIX accumulated primarily within the plasma
membranes of HeLa cells expressing R433K, as visualized by
the characteristic red fluorescence; however, PPIX build-up was
also apparent within the cells (Figures 5C, columns 3–5 and 5D,
columns 3–5). Thus, it appears that much of the PPIX produced in
the mitochondria eventually accumulates in the plasma membrane, entirely consistent with the fact that PPIX is a relatively
lipophilic molecule. Of note, PPIX accumulated in not only
transfected cells, but also in surrounding cells, indicating that
PPIX could leave the transfected cells and be taken up by nearby
cells (Figures 5, columns 3–5 and 5D, columns 3–5C). It is very
likely that, additionally, PPIX accumulated in organelle membranes within the cell, such as in the mitochondrion, but since
PPIX photobleached within a few seconds under the conditions
utilized here, it was not possible to obtain high-resolution organelle
images with our current microscopic parameters. Finally, the
cobblestone-like morphology, instead of a slightly elongated shape,

PPIX Primarily Accumulates and Localizes at the Plasma
Membrane in HeLa Cells Expressing R433K
To evaluate cellular intactness and accumulated PPIX distribution in the transfected HeLa cells, we used confocal microscopy
to visualize the fluorescent PPIX in individual HeLa cells
(Figure 5A) and HeLa cells transfected with either the pIRES2ZsGreen1 vector (Figure 5B) or pEF31 (harboring R433K)
(Figures 5C and 5D). Transfected cells were grown in medium
supplemented with 100 mM glycine for 18 hours in preparation
for imaging. The outline of intact cells, and thus their morphological integrity, was evident in the three cases. As expected, green
fluorescence was visualized in the transfected (Figures 5B, columns
2, 4 and 5, 5C, columns 2, 4 and 5 and 5D, columns 2, 4 and 5)
but not control HeLa cells (Figure 5A, columns 2, 4 and 5). In fact,
green fluorescence, arising from the soluble ZsGreen1 green
fluorescent protein was observed evenly distributed throughout the
cytoplasm of the HeLa cells transfected with either pIRES2PLOS ONE | www.plosone.org
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Figure 4. Stable expression of murine ALAS2 variants in K562 cells results in PPIX accumulation when culture medium is
supplemented with either glycine or deferoxamine. (A) PPIX fluorescence 18 hours after supplementation of the culture medium with glycine
to yield 10 mM and 100 mM final concentrations. Normalized fluorescence values were obtained by first dividing the mean PPIX fluorescence by the
mean ZsGreen1 fluorescence for each cell population and secondly dividing by the mean PPIX fluorescence/ZsGreen1 fluorescence ratio of the
pIRES2-ZsGreen1-transfected cells. (B) PPIX fluorescence 18 hours after supplementation of the culture medium with deferoxamine to a final
concentration of 100 mM (+D). (C) PPIX fluorescence of K562 cell populations supplemented with glycine to a 100 mM final concentration. The blue
area represents cells that do not express ZsGreen1, and the green area represents the population that expresses ZsGreen1. K562 cells that express
ZsGreen1 are not affected by glycine supplementation of the culture medium (upper plots), while cells that express WT exhibit a significant increase
in PPIX fluorescence when the culture medium is supplemented with glycine (lower plots). (D) PPIX fluorescence of K562 cell populations grown in
culture media containing 100 mM deferoxamine. Cell growth in the presence of deferoxamine significantly increases the PPIX fluorescence in K562
cells expressing WT, but does not affect PPIX fluorescence in cells expressing only ZsGreen1 or HPVT, as indicated by the number of cells within the
red dotted-line boxes.
doi:10.1371/journal.pone.0093078.g004

of the HeLa cells may result from the cell density and/or the
nature of the growth surface. HeLa cells tend to adopt a more
cobblestone-like appearance as cultures approach confluence and
the HeLa cell morphology varies with the adhesion surface.

R433K and treated with paclitaxel exhibited the highest
percentage of up to 50% cell death (Figure 6A–B). Combination
of paclitaxel with mALAS2-induced PPIX accumulation and light
treatments exhibited an additive effect in causing death in HeLa
cells.

ALAS2-induced PPIX Accumulation Followed by Light
Exposure Combined with Paclitaxel Treatment Causes
Cell Death

Supplementation of Cell Culture Medium with Glycine
Enhances Phototoxicity and Cell Death in Malas2expressing HeLa Cells

Both propidium iodide and DAPI staining were utilized to assess
cell viability after mALAS2-induced PPIX accumulation, light
exposure, and paclitaxel treatment, based on the specific
fluorescence emission of each dye when bound to the DNA of
intact cells. Stains were added to cell samples 48 hours after
transfection, and the fluorescence of DNA-bound propidium
iodide and DAPI were measured by flow cytometric analysis using
the respective fluorescence emission maxima of 613 nm and
460 nm. Expression of WT or HPVT did not significantly increase
cell death following light exposure. However, expression of R433K
caused a statistically significant (p,0.05) increase in cell death of
up to 30%, as measured both by propidium iodine (Figure 6A) and
DAPI (Figure 6B) staining, in comparison to expression of
ZsGreen1 alone. Addition of paclitaxel increased cell death in all
samples, including controls, by 10–25%. HeLa cells expressing
PLOS ONE | www.plosone.org

The phototoxicity and subsequent cell death caused by
mALAS2-induced PPIX accumulation, when the culture medium
was supplemented with glycine, were also investigated in HeLa
cells. Cell viability was measured using propidium iodide (data not
shown), DAPI staining, and MTT assays (Figure 7) 24 hours posttransfection, 18 hours after glycine addition, and 4 hours after
ALA addition. Significant cell death was ascribed to those samples
that exhibited more cell death compared to the pIRES2ZsGreen1-transfected cells with the same glycine concentration
as determined by Student’s t-tests (p,0.05). Transfection of HeLa
cells with the pIRES2-ZsGreen1 plasmid caused a decrease in cell
viability by an average of 30%, which can be attributed to the mild
cytotoxicity of the transfection reagents [54].
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Figure 5. Fluorescence microscopy of HeLa cells expressing GFP and the R433K mALAS2 variant. From left to right for each row, the
panels correspond to (1) brightfield, (2) green fluorescence, (3) red fluorescence, (4) superimposed green and red fluorescence, and (5) superimposed
brightfield, green fluorescence, and red fluorescence images. (A) HeLa cells grown to confluence in culture medium with 100 mM glycine. (B) HeLa
cells transfected with pIRES2-ZsGreen1 and grown to confluence in culture medium with 100 mM glycine. (C) HeLa cells transfected with pEF31,
which expresses the R433K variant from the CMV promoter in the pIRES2-ZsGreen1 vector (Table 1), and grown to confluence in culture medium with
100 mM glycine. (D) HeLa cells transfected with pEF31 and grown to subconfluence (i.e., 80% confluence) in culture medium with 100 mM glycine.
Pictures were obtained 24 hours after transfection and 18 hours after glycine supplementation. ZsGreen1 (green) is present throughout the cell, while
PPIX (red) accumulates at the plasma membrane of cells expressing R433K and surrounding cells.
doi:10.1371/journal.pone.0093078.g005

Expressing WT, regardless of the glycine concentration in the
culture medium, caused approximately 70% cell death following
light exposure, as measured by DAPI staining (Figure 7A–B). In
the MTT assays, expression of WT only caused statistically

significant cell death (p,0.05) with supplementation of 100 mM
glycine, in which case only an average of 15% of cells remained
viable (Figure 7C). HeLa cells expressing HPVT or R433K did
exhibit a glycine-dependent increase in cell death when the glycine

Figure 6. Light-induced cell death of HeLa cells expressing mALAS2 variants. (A) Cell death measured by changes in DNA-bound
propidium iodide fluorescence. (B) Cell death measured by changes in DNA-bound DAPI fluorescence. HeLa cells were transfected with expression
plasmids for either wild type (WT) or mALAS2 variants and treated with 10 nM paclitaxel 4-hour post-transfection. 48 hours after transfection, cells
were stained and analyzed by flow cytometry. Cell death percentage values were compared to that of the pIRES2-ZsGreen1-transfected cells control.
Each data set represents three separate experiments 6 standard deviation (*p,0.05 and **p,0.01, Student’s t-test).
doi:10.1371/journal.pone.0093078.g006
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Figure 7. Light-induced cell death in murine ALAS2 variants-expressing HeLa cells cultured in a medium supplemented with
glycine. (A) Cell death as assessed by DAPI fluorescence. Six hours after transfection of the HeLa cells with the different expression plasmids, the cells
were grown for an additional 18 hours in medium without or with glycine (10 mM or 100 mM). Cell death percentage values are representative of
three separate experiments 6 standard deviation (*p,0.05, Student’s t-test). For control and ALA-treated cells, cell death was calculated by dividing
the number of DAPI-stained cells by the total number of cells. For ZsGreen1-, WT-, HPVT-, and R433K-expressing cells, cell death was calculated from
the ZsGreen1-positive cell populations by dividing the number of DAPI-stained cells by the total number of ZsGreen1-positive cells. (B) Cell death in
HeLa cell populations grown in culture medium supplemented with glycine to a final concentration of 100 mM. The percentage of cells in each
quadrant is written in the corners of each dot plot. (C) Cell viability as measured by metabolism of 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT). Cells were transfected 24 hours before light treatment, and 100 mM glycine was added 18 hours before
light treatment. Cell viability percentage values are normalized to MTT metabolism in healthy, untreated HeLa cells and are representative of at least
three separate experiments 6 standard deviation (*p,0.05, Student’s t-test). ‘‘Control’’ refers to non-transfected HeLa cells.
doi:10.1371/journal.pone.0093078.g007

For example, there is no specific mechanism that targets PPIX to
tumor cells after ALA has been applied, other than a slightly
preferential uptake of photosensitizers by hyperproliferating cells
[58]. Consequently, normal tissue can be damaged from the
procedure due to unintentional exposure to light resulting in pain,
and conversely, not all hyperproliferating cells necessarily become
highly sensitized [55,59]. In an attempt to restrict photosensitivity
by biological, rather than just chemical or physical means, an
adenovirus expressing human ALAS2 with mutated HRMs was
generated and H1299 lung carcinoma cells were successfully
infected [40]. The adenovirus-infected H1299 cells accumulated
more PPIX and became more photosensitive than cells supplied
with ALA in their media, indicating that delivery of ALAS to
tumors could potentially be a useful tool for PDT not only for
better targeting, but also for greater photosensitivity [40].
However, the cell death was only 26% even in the presence of
deferoxamine [40], leading us to postulate that one or more highly
active variants of mALAS2 [31,35] would increase PPIX

concentration reached 100 mM as measured by both DAPI
staining and MTT assays. When 100 mM glycine was added, cells
expressing HPVT decreased from an average of 81% viable to
13% viable, and cells expressing R433K decreased from 58%
viable to 25% viable as measured by MTT assays (Figure 7C).
ALA treatment did not cause significant cell death (p.0.05),
regardless of glycine concentration, when measured by either
DAPI staining or MTT assays.

Discussion
Photodynamic therapy (PDT) is a widely utilized clinical
procedure for many types of cancer, as well as dermatological
conditions such as psoriasis and schleroderma [55–57]. PDT is
often initiated by application of the pro-drug 5-aminolevulinic acid
(ALA) to the patient in order to photosensitize the tissue to be
treated [49]. ALA-PDT is very effective, has minimal side effects
and is being tested in numerous clinical trials on a wide-spectrum
of cancers [49]. There are, however, some limitations to ALAPDT and other PDTs that provide opportunities for improvement.
PLOS ONE | www.plosone.org
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degrees of mobility [35]. Since the mutations in HPVT
destabilized the active site loop and altered the protein conformation [35], it would not be surprising if this variant had a
decreased cellular stability. Additionally, the HPVT mutations
may affect protein-protein interactions, specifically the ability of
mALAS2 to interact with a known binding partner, succinyl-CoA
synthetase [62].
The simple addition of the non-toxic substrate glycine to the cell
media increased PPIX production by WT, HPVT, and R433K
significantly. When the culture medium was supplemented to a
final concentration of 10 mM or 100 mM glycine, PPIX
production in HeLa cells expressing WT was increased by more
than 4- and 6-fold for each concentration, respectively (Figure 3).
In K562 cells expressing WT, the effect was even larger, as PPIX
increased by more than 5- and 10-fold for 10 mM and 100 mM
glycine, respectively (Figure 4A and 4C). The slightly higher
increases in PPIX concentrations in the K562 cells when treated
with glycine could be due to the stable expression of ALAS2 versus
the transient transfection used in the HeLa cells. However, the
ability of the K562 cells to tolerate higher expression of WT and
production of PPIX, in comparison to HeLa cells, might also be
attributable to their erythroid lineage. K562 cells are of the
erythroleukemic cell type, and bear some proteomic resemblance
to undifferentiated erythrocytes [51,63] and express endogenous
ALAS2. Thus while expressing ALAS2 in HeLa cells introduces
an enzyme that does not normally exist in epithelial cells, K562
cells may adapt more easily to the expression and up-regulation of
the heme biosynthetic pathway. It seems likely that the capacity of
mALAS2 to accumulate PPIX will be found to vary in other
mammalian cell types as well.
Supplementing the culture medium of K562 cells expressing
WT with 100 mM deferoxamine, an iron-chelator previously
shown to increase the amount of PPIX in ALAS adenovirusinfected H1299 cells [40], resulted in increase in the mean PPIX
fluorescence per cell (Figure 4B and 4D), but it was much less than
with glycine supplementation. However, the modest increase was
similar to what Gagnebin et al. [40] observed in the ALAS
adenovirus-infected cells, suggesting the much larger increases
reported here with R433K and glycine supplementation represent
substantial advancements in our ability to overproduce PPIX in
mammalian cells. R433K is only twice as active as WT in vitro, and
it is reasonable to believe that significantly more active variants
could be readily produced via directed evolution, and that these
variants would facilitate even greater levels of PPIX accumulation,
perhaps to the point of expanding the clinical applicability of
PPIX-based PDT.
The HeLa cells that accumulated the highest amount of PPIX
were those expressing R433K. The R433K mutation was analyzed
in 1998 by Tan et al. [31] in a study that identified the nearby
R439 as being a conserved residue in many a-family PLPdependent enzymes, as well as being involved in binding of the
amino acid substrate during catalysis [31]. In that study, the
kinetic parameters were defined for R439L, R439K, R433L, and
R433K. Although not the primary focus of the article, the kinetic
parameters for R433L were found to be comparable to those of
the wild-type at 37uC, while for R433K the kcat was increased by
two-fold, with no effect on the Michaelis constants, resulting in a
doubling of catalytic efficiency for both substrates [31]. In the
results detailed here, expression of R433K in HeLa cells produced
a 2- to 3-fold increase in PPIX in comparison to WT, and a 4- to
6-fold increase in PPIX fluorescence in comparison to cells
transfected with the pIRES2-ZsGreen1 vector control or HeLa
cells alone (Figure 2). When the culture medium was supplemented with glycine, PPIX accumulation increased by 13- to 15-fold in

accumulation, phototoxicity, and targeted cell death sufficiently to
make the approach more clinically attractive.
To explore the ability of mALAS2 variants to cause accumulation of PPIX in mammalian cells, we transfected cells, of both
erythroid and non-erythroid lineages, with murine ALAS2expressing plasmids, and quantified the PPIX fluorescence using
FACS analysis. In HeLa cells, we transfected plasmids encoding
mALAS2 both with and without mutated presequences and with
or without mutations in the mature enzyme sequence (Table 1,
Figure 1). As with many mitochondrial proteins, ALAS2 is
synthesized in the cytosol and contains a sequence at its Nterminus that targets ALAS2 for mitochondrial import after its
synthesis [18]. Within the N-terminus of the ALAS2 precursor,
there are three HRMs as recognized by adjacent cysteine-proline
residues that have the potential to bind heme. The HRMs located
within the presequence of ALAS2 (C11 and C38) have been
shown to bind heme [24] and subsequently inhibit the mitochondrial import of ALAS2 [18]. Our experiments support the existing
data that the cysteines in the HRMs bind heme, and that mutation
of these HRMs relieve the inhibition of mitochondrial import, thus
resulting in increased mature, functional ALAS2, as reflected by
increased cellular concentrations of PPIX when the HRMs are
mutated (Figure 2A). In our study, when the HRMs in the
presequences of the mALAS2 constructs were mutated to relieve
heme inhibition on mitochondrial import, there were significant
increases in PPIX accumulation in HeLa cells expressing WT,
HPVT, and R433K (Figure 2A–B).
We tested several mALAS2 variants, covering a range of in vitro
activity from undetectable to higher than wild-type, for capacity to
stimulate PPIX accumulation [31,35,36,60]. Transfection of HeLa
cells with the negative control plasmid harboring K313AY resulted
in no PPIX increase, as expected (Figure 2A). The mutation of
K313 leads to undetectable enzymatic activity in vitro, attributable
to the role of K313 in formation of a Schiff-base linkage with the
PLP cofactor [36], and its additional function as a general base
catalyst during the ALAS-catalyzed reaction [3,28,36,61]. In
preliminary studies with HeLa cells, it was observed that
expression of HPVTY, which has seven mutations in its active
site loop, yielded significantly more accumulated PPIX than
expression of the pIRES2-ZsGreen1 vector control plasmid.
HPVTY was chosen for this study as the seven mutations of
non-conserved residues in the active site loop resulted in the most
active recombinant protein isolated from a variant library at 20uC
[35]. Lendrihas et al. [35] hypothesized that these mutations in the
active site loop, which increase both hydrophilicity and basicity,
destabilize the loop by both increasing solubility and eliminating
hydrophobic and electrostatic interactions that would typically act
to stabilize the loop in its closed confirmation. However, the
hyperactivity of HPVTY was temperature-dependent; while at a
temperature of 20uC these seven mutations increased the kcat value
of the recombinant, mature enzyme to more than 10 times of that
of the WT enzyme, at 35uC the kcat values were nearly the same
[35]. While the levels of accumulated PPIX in HeLa cells
expressing HPVT were significantly affected by supplementation
with glycine (p,0.01), those in K562 cells expressing HPVT were
only modestly increased when the medium was supplemented with
100 mM glycine. However, the HPVT-promoted PPIX concentration enrichments were much lower than those in cells
expressing WT or R433K (Figures 3 and 4). The relatively low
levels of PPIX associated with HPVT expression are presumably
due to the temperature-dependent activity profile of this particular
mALAS2 variant. HPVT was isolated from a library of mALAS2
variants engineered to possess greater enzymatic activity than wild
type mALAS2 by targeting the active site loop to acquire different
PLOS ONE | www.plosone.org
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antibody.] and distinct modulation of the enzymatic activity
between ALAS2 and variants cannot be ruled out as possibilities.
Treatment with 100 mM ALA, a positive control for PPIX
accumulation, caused a similar cell death after light exposure to
expression of the ZsGreen1 protein alone. In summary, the highest
cell death was seen in light-treated HeLa cells expressing
ZsGreen1 and either WT, HPVT, or R433K, in culture medium
supplemented with 100 mM glycine. The total cell death was
observed to be as high as 90% in the cells expressing both
ZsGreen1 and R433K. This represents a substantial improvement
upon the 26% cell death reported previously [40], and indicates
that this approach, if carefully developed, may eventually find
some clinical utility.
Because ALAS2, especially highly stable and active variants of
ALAS2, would be useful in the development of multiplex cancer
treatments involving PDT, we experimented with combination
PDT and drug treatments of HeLa cells. Paclitaxel (Taxol) is
currently approved in the United States for the treatment of
AIDS-related Kaposi sarcoma [70], breast cancer [71], non-small
lung cell lung cancer [72], and ovarian cancer [73]. Paclitaxel
induces apoptosis in cancer cells by binding to tubulin and
inhibiting the disassembly of microtubules, thereby resulting in the
inhibition of cell division [46,74]. As expected, paclitaxel did not
affect PPIX accumulation, as indicated by the similar mean PPIX
fluorescence values between untreated and paclitaxel-treated cells
(Figure 2B). However, paclitaxel had an additive effect to PDT
and increased cell death in all samples by 10–25%. HeLa cells
expressing R433K treated with paclitaxel exhibited the highest
percentage of cell death (Figure 6A–B). Ever since PDT was first
shown to be able to elicit an immune response [75], many recent
advances in PDT are aiming toward creating PDT-generated
cancer vaccines [76]. Using highly active and stable ALAS2
variants as part of a vaccine strategy for photosensitization may be
useful for this vaccine approach. Further experiments, both in cell
culture and live animals, are necessary to test for potential immune
response stimulated by ALAS2-PDT.
In this study, we have shown that transfecting mammalian cells,
of both erythroid and non-erythroid lineages, with mALAS2
variants, is an effective way to stimulate cellular PPIX accumulation. Furthermore, supplementing the culture medium with
glycine vastly increases the intracellular PPIX levels when cells
express either WT or R433K. These data offer new ways to
accumulate high levels of the photosensitizer PPIX in cancer cells
for more targetable and efficient PDT. Human ALAS2 variants
with higher than normal activity are now known to occur in
nature, and are associated with a form of erythropoietic
protoporphyria known as X-linked dominant protoporphyria,
which is characterized by a 24-fold increase in erythrocyte PPIX
concentrations [39]. It would be appropriate if these variants were
eventually utilized in PDT, and could thereby allow clinicians to
exploit one disease to treat or cure others.

comparison to cells transfected with the pIRES2-ZsGreen1 vector
control or HeLa cells alone, and represented the conditions for the
highest cellular PPIX accumulation. Given that within these
samples there were cells fluorescing with PPIX that were not
ZsGreen1-expressing (Figure 3B), some of the PPIX produced in
the R433K- and WT-expressing HeLa cells appears to have been
transported out of the cells into the culture medium, where it was
then taken up by non-transfected cells. These populations of redfluorescing cells were comparable to those cells in culture medium
supplemented with ALA (Figure 3B). This is a very important
finding in terms of the potential of these constructs for
photodynamic therapy, as it indicates that the PPIX produced
within a delivery cell could be transported into surrounding
diseased tissue and accumulate to clinically relevant levels.
The subcellular distribution of a photosensitizing agent might
have important consequences in regards to PDT efficacy [64].
Fluorescence microscopy was successfully utilized to visualize PPIX
accumulation in R433K expressing HeLa cells. Due to the
extremely short time (a few seconds) it took for PPIX to
photobleach, the resolution could not be optimized for visibility of
individual organelles such as mitochondria and nuclei. However, it
was possible to observe that PPIX had accumulated in the plasma
membranes of the R433K expressing cells; and this fluorescence
was not seen in the pIRES2-ZsGreen1 vector-expressing cells
(Figure 5). It also appears that PPIX can actively exit the transfected
cells, potentially via ABC transporters, and enter surrounding cells.
Presumably, the lipophilic PPIX accumulated in the organelle
membranes as well, but direct microscopic confirmation of PPIX
accrual in organelle membranes awaits approaches resulting in
better resolution than we were able to achieve here.
In order to study the photosensitivity of cells that accumulated
PPIX (caused by expression of WT, HPVT, and R433K), we
performed light treatments using an incandescent lamp, which
emits light in the visible and infrared spectral regions (400–
1000 nm). The cells were exposed for 10 minutes before FACS
analysis of PPIX and cell death. Expression of the ZsGreen1
protein alone caused a toxicity that was independent of light
treatment, and thus significant cell death was measured against the
pIRES2-ZsGreen1 vector-transfected cells (p,0.05) as opposed to
HeLa cells alone (Figure 7). Regardless of glycine concentration,
the expression of WT led to a significant increase in cell death by
1.4- to 2-fold. R433K and HPVT, when the culture medium was
supplemented with 100 mM glycine, also caused significant
increases in cell death by 2.1- and 1.6-fold, respectively. With no
or 10 mM glycine supplementation the error was too high for any
of the increases to be significant, although there was a trend
towards increased cell death. For WT and R433K, increased
PPIX accumulation correlates with increased cell death after light
treatment. In spite of the more modest increases in PPIX
accumulation, light-induced death also occurred in HPVTexpressing cells. This finding led us to suggest that toxicity
inherent to the overproduced HPVT protein is the other
contributing factor to cell death. Although purified recombinant,
mature HPVT is more active than WT at 37uC (with an
enhancement of approximately 1.5 in the kcat value at 37uC vs. a
15.5-fold increased kcat at 20uC) [65], when expressed in
mammalian cells, HPVT is not as active as WT, as determined
by PPIX fluorescence. Since expression of HPVT paired with
glycine supplementation caused significant cell death (Figure 7),
the potential role of another toxic heme pathway intermediate,
such as the pro-oxidant ALA [66–69], in causing cell death, is
plausible. However, at the present, different levels of protein
expression [Quantification of ALAS2 and variant protein levels
was not feasible due to the unavailability of a functional ALAS2
PLOS ONE | www.plosone.org

Supporting Information
Figure S1 Porphyrin accumulation in HeLa cells
through expression of mALAS2 compared to supplementation of culture medium with ALA. HeLa cells transfected
with mALAS2 variants were analyzed 24 hours after transfection,
and ALA-treated HeLa cells were analyzed 4 hours after addition
of ALA to the culture medium. Mean PPIX fluorescence values
were compared to those of the pIRES2-ZsGreen1-transfected cells
control; each of PPIX data sets is representative of three separate
experiments 6 standard deviation [a.u., arbitrary units].
(TIF)
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